揭示镥-177标记的帕妥珠单抗的潜力：靶向HER 2受体用于治疗诊断应用。 - Suppr

Unravelling the Potential of Lutetium-177 Labeled Pertuzumab: Targeting HER 2 Receptors for Theranostic Applications.

作者信息

Sharma Rohit, Mukherjee Archana, Mitra Jyotsna Bhatt, Sarma Haladhar Dev

机构信息

Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, Maharashtra, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai, Maharashtra, India.

出版信息

Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):419-425. doi: 10.1016/j.ijrobp.2022.07.029. Epub 2022 Jul 25.

DOI:10.1016/j.ijrobp.2022.07.029

PMID:35901977

Abstract

摘要

相似文献

Unravelling the Potential of Lutetium-177 Labeled Pertuzumab: Targeting HER 2 Receptors for Theranostic Applications.揭示镥-177标记的帕妥珠单抗的潜力：靶向HER 2受体用于治疗诊断应用。

Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):419-425. doi: 10.1016/j.ijrobp.2022.07.029. Epub 2022 Jul 25.

[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.（177）帕妥珠单抗：针对HER-2阳性肿瘤细胞的实验研究。

Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1457-62. doi: 10.1007/s00259-005-1902-0. Epub 2005 Sep 29.

Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.用¹⁷⁷Lu标记的抗HER2纳米抗体进行靶向放射性核素治疗。

Theranostics. 2014 Apr 25;4(7):708-20. doi: 10.7150/thno.8156. eCollection 2014.

(177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation.靶向表皮生长因子受体（EGFR）和人表皮生长因子受体2/神经原癌基因（HER2/c-neu）的镥-177/钇-90中等亲和力单克隆抗体：制备与临床前评估

Recent Results Cancer Res. 2013;194:301-17. doi: 10.1007/978-3-642-27994-2_16.

[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.[177镥]帕妥珠单抗：HER-2表达异种移植瘤的实验性治疗

Cancer Res. 2007 Jan 1;67(1):326-31. doi: 10.1158/0008-5472.CAN-06-2363.

Preparation of Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR-positive cancers: Comparison of DOTA and CHX-A″-DTPA as bifunctional chelators.用于表皮生长因子受体阳性癌症放射免疫治疗的镥标记尼妥珠单抗的制备：双功能螯合剂DOTA和环己二胺四乙酸（CHX-A″-DTPA）的比较

J Labelled Comp Radiopharm. 2019 Apr;62(4):158-165. doi: 10.1002/jlcr.3707. Epub 2019 Feb 17.

Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.（177）Lu-尼妥珠单抗的临床前评估：一种针对表皮生长因子受体过表达肿瘤的放射免疫治疗的潜在工具。

Cancer Biother Radiopharm. 2011 Jun;26(3):287-97. doi: 10.1089/cbr.2010.0916. Epub 2011 Jun 28.

Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of Lu-Nimotuzumab.用不同剂量的 Lu-Nimotuzumab 处理低表达 EGFR 的 A549 和高表达 EGFR 的 A431 肿瘤细胞，诱导不同的细胞阻滞和分子反应。

Int J Radiat Biol. 2020 Sep;96(9):1144-1156. doi: 10.1080/09553002.2020.1793012. Epub 2020 Jul 23.

Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.在胆管癌中 EGFR、HER2 和 HER3 的过表达和基因扩增，以及使用 HER2 靶向抗体 pertuzumab 进行治疗的可能性。

J Gastroenterol. 2015 Apr;50(4):467-79. doi: 10.1007/s00535-014-0984-5. Epub 2014 Aug 12.

Clinical Dose Preparation of [Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [Lu]LuCl for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression.使用中特异性放射性活度 [Lu]LuCl3 对具有 HER2 受体过表达的乳腺癌和上皮性卵巢癌进行放射性免疫治疗的 [Lu]Lu-DOTA-Pertuzumab 的临床剂量制备。

Cancer Biother Radiopharm. 2022 Jun;37(5):384-402. doi: 10.1089/cbr.2021.0230. Epub 2022 May 16.

引用本文的文献

The role of radiotheranostics in personalized treatment for breast cancer.放射治疗诊断学在乳腺癌个性化治疗中的作用。

Med Oncol. 2025 Jul 11;42(8):322. doi: 10.1007/s12032-025-02825-y.

Theranostic Approaches for Gastric Cancer: An Overview of In Vitro and In Vivo Investigations.胃癌的诊疗一体化方法：体外和体内研究综述

Cancers (Basel). 2024 Sep 28;16(19):3323. doi: 10.3390/cancers16193323.

Dual targeting with Ra/Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach.用镭/铅共轭物进行双重靶向用于播散性癌症的靶向α治疗：一种概念性方法。

Front Med (Lausanne). 2023 Jan 17;9:1051825. doi: 10.3389/fmed.2022.1051825. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Unravelling the Potential of Lutetium-177 Labeled Pertuzumab: Targeting HER 2 Receptors for Theranostic Applications.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献